"To solve the pain points in fundus and microsurgery operations, the rigidity is very strong. "This article is the original of IPO.
Author Uncle C.
According to the IPO, Hangzhou Dishi Medical Biotechnology Co., Ltd. (hereinafter referred to as "Dishi Medical") recently completed tens of millions of yuan in Pre-A++ round of financing, invested by Dachen Caizhi, and Kaicheng Capital continued to serve as the exclusive financial advisor. This is also the company's third funding round in a year. The funds from this round of financing will be mainly used to promote the NMPA registration of ophthalmic surgical robots and promote the research and development of product lines such as microsurgical robots.
Founded in July 2021, Dishi Medical is a national technology-based small and medium-sized enterprise focusing on the field of ultra-microsurgery. Its founding team comes from Germany, the world's top robotics and artificial intelligence laboratories, and the world's top 500 German pharmaceutical companies. Up to now, Dishi Medical has applied for and authorized a number of invention patents in the United States and China, and has carried out a number of scientific research projects in the field of surgical robots with several well-known medical institutions in China.
The R&D of ophthalmic surgical robots is essential to address pain points in fundus and microsurgery. With its personalized combination of medicine and engineering, multi-freedom based on master-slave control and original flexible structure technology, Dishi Medical has achieved a motion accuracy of up to 3 microns. Since July 2023, when the "Dishi Weifeng" ophthalmic surgical robot completed the first human clinical application case in Asia at Zhejiang Provincial People's Hospital, a number of scientific research clinical cases have been successfully completed, and the postoperative results are good. At present, the company has officially launched the clinical trial of NMPA registration to further verify the safety and efficacy of its products. In addition, the company's microsurgical robots have also entered the prototype development stage.
The first clinical application of "Dishi Weifeng" (**Dishi Medical).
Dr. Cui Di, CEO of Dishi Medical, said: "The smooth application of the 'Dishi Weifeng' ophthalmic surgical robot in scientific research and clinical research has given our team great confidence, and we are grateful to Dachen Caizhi for recognizing Dishi and providing strong support for the ophthalmic surgical robot to enter a new stage of clinical registration. Next, we will further expand the application of medical robots in the field of microsurgery represented by ophthalmic surgical robots, so as to become a dexterous and precise hand for doctors in ultra-microsurgery, and bring light to patients who were difficult to achieve in the past. ”
Dr. Yu Peifeng, Investment Director of Dachen Caizhi, said: "Different from specialized surgical robots such as laparoscopic surgical robots and orthopedics, fundus and ultra-microsurgical robots solve the pain points in fundus and microsurgery operations due to their ultra-high precision. We have been following the company for a year and a half, and we have witnessed the high execution efficiency of the team led by Cui Bo, and we look forward to the future of Dishi all the way through the thorns and thorns, and we will achieve steady and far-reaching results. ”
Zou Guowen, Founding Partner of Kaicheng Capital, said: "As a high-quality enterprise in the surgical robot industry, Dishi Medical has been able to go through the market cycle and obtain three consecutive rounds of financing within one year, which fully reflects the high recognition of the company by the capital side. Dishi Medical's surgical robot products have broken through the limit of human physiological operation, assisted doctors to complete ultra-difficult surgeries, and had strong clinical needs, hoping to be able to be introduced to the market as soon as possible to benefit more patients. ”